Total Valuation
N4 Pharma has a market cap or net worth of €19.46M. The enterprise value is €3.06M.
Market Cap€19.46M
Enterprise Value€3.06M
Share Statistics
N4 Pharma has 1,775,721,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,775,721,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
N4 Pharma’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -103.14%.
Return on Equity (ROE)-1.13
Return on Assets (ROA)-1.03
Return on Invested Capital (ROIC)-103.14%
Return on Capital Employed (ROCE)-1.03
Revenue Per Employee1.82K
Profits Per Employee-301.25K
Employee Count4
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of N4 Pharma is ―. N4 Pharma’s PEG ratio is 0.07.
PE Ratio―
PS Ratio523.56
PB Ratio3.55
Price to Fair Value3.55
Price to FCF-3.28
Price to Operating Cash Flow-4.84
PEG Ratio0.07
Income Statement
In the last 12 months, N4 Pharma had revenue of 7.26K and earned -1.21M in profits. Earnings per share was >-0.01.
Revenue7.26K
Gross Profit0.00
Operating Income-1.10M
Pretax Income-1.10M
Net Income-1.21M
EBITDA-1.10M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.16M and capital expenditures -3.00, giving a free cash flow of -1.16M billion.
Operating Cash Flow-1.16M
Free Cash Flow-1.16M
Free Cash Flow per Share>-0.01
Dividends & Yields
N4 Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-35.32
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
N4 Pharma upcoming earnings date is Sep 24, 2026, TBA (Confirmed).
Last Earnings DateJun 23, 2026
Next Earnings DateSep 24, 2026
Ex-Dividend Date―
Financial Position
N4 Pharma as a current ratio of 11.93, with Debt / Equity ratio of 0.00%
Current Ratio11.93
Quick Ratio11.93
Debt to Market Cap0.00
Net Debt to EBITDA0.98
Interest Coverage Ratio0.00
Taxes
In the past 12 months, N4 Pharma has paid 104.12K in taxes.
Income Tax104.12K
Effective Tax Rate-0.09
Enterprise Valuation
N4 Pharma EV to EBITDA ratio is -2.47, with an EV/FCF ratio of -2.35.
EV to Sales374.97
EV to EBITDA-2.47
EV to Free Cash Flow-2.35
EV to Operating Cash Flow-2.35
Balance Sheet
N4 Pharma has €1.08M in cash and marketable securities with €0.00 in debt, giving a net cash position of €1.08M billion.
Cash & Marketable Securities€1.08M
Total Debt€0.00
Net Cash€1.08M
Net Cash Per Share<€0.01
Tangible Book Value Per Share<€0.01
Margins
Gross margin is 0.00%, with operating margin of -15199.56%, and net profit margin of -16589.87%.
Gross Margin0.00%
Operating Margin-15199.56%
Pretax Margin-15199.56%
Net Profit Margin-16589.87%
EBITDA Margin-15199.56%
EBIT Margin-15199.56%
Analyst Forecast
The average price target for N4 Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-1.30%
EPS Growth Forecast45.95%